Interventions of Interest:

  • Crizanlizumab (Adakveo®, Novartis)
  • Voxelotor (Oxbryta®, Global Blood Therapeutics)
  • L-gluatmine (Endari, Emmaus Medical)

Due to the COVID-19 pandemic, we have decided to indefinitely postpone our public meeting on therapies for sickle cell disease (originally slated for March 26, 2020). Please refer to the sickle cell disease evidence report for our most updated findings.

Date of review: March 2020

For questions, please contact

Final Documents

Below you will find the final documents from the assessment review process: